Heron Therapeutics (HRTX) Financials: History & Chart

Heron Therapeutics, Inc.(HRTX)

Biotechnology · Cary, NC

$0.33-0.04 (-10.76%)

Delayed quote: Oct 6, 2026, 2:49 PM EDT

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.

Cary, NC

128 employees

www.herontx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Craig Alexander Collard

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	151.18M	37.67M	34.71M	40.59M	38.21M	37.20M	38.90M	40.78M	32.81M
Cost of Goods Sold	45.24M	11.57M	10.64M	7.65M	15.38M	9.86M	8.46M	10.23M	9.46M
Gross Profit	105.94M	26.09M	24.07M	32.94M	22.83M	27.34M	30.45M	30.55M	23.35M
Gross Profit Margin	70.1%	69.3%	69.4%	81.2%	59.7%	73.5%	78.3%	74.9%	71.2%
Total Operating Expenses	116.80M	28.14M	28.84M	32.90M	26.92M	28.98M	27.29M	26.38M	27.81M
Research & Development	12.30M	2.70M	2.38M	3.75M	3.47M	2.93M	2.28M	3.18M	4.46M
Selling, General & Administrative	104.50M	25.44M	26.45M	25.68M	26.92M	26.05M	25.01M	23.20M	23.34M
Operating Income (EBIT)	-10.86M	-2.04M	-4.76M	38K	-4.09M	-1.64M	3.15M	4.17M	-4.46M
Operating Margin	-7.2%	-5.4%	-13.7%	0.1%	-10.7%	-4.4%	8.1%	10.2%	-13.6%
Income Before Tax (EBT)	-34.05M	-5.49M	-8.11M	-2.95M	-17.50M	-2.38M	2.63M	3.66M	-4.85M
Interest Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	3.90M	N/A	N/A	1.00M	2.90M	N/A	500K	4.43M	500K
Other Income/Expense	-23.18M	-3.44M	-3.35M	-2.99M	-13.40M	-744K	-519K	-510K	-390K
Net Income	-34.05M	-5.49M	-8.11M	-2.95M	-17.50M	-2.38M	2.63M	3.66M	-4.85M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-22.5%	-14.6%	-23.4%	-7.3%	-45.8%	-6.4%	6.8%	9.0%	-14.8%
EBITDA	-8.11M	-1.59M	-4.24M	1.20M	-3.48M	-1.03M	3.71M	4.75M	-3.88M
EBITDA Margin	-5.4%	-4.2%	-12.2%	3.0%	-9.1%	-2.8%	9.5%	11.7%	-11.8%
Depreciation & Amortization	2.76M	452K	529K	1.16M	615K	611K	551K	581K	581K
EPS Basic	-0.19	-0.03	-0.04	-0.02	-0.10	-0.02	0.02	0.02	-0.03
EPS Diluted	-0.19	-0.03	-0.04	-0.02	-0.10	-0.02	0.02	0.02	-0.03
Weighted Average Basic Shares	190.34M	190.34M	189.65M	166.71M	170.35M	154.02M	153.49M	153.15M	152.83M
Weighted Average Diluted Shares	190.34M	190.34M	189.65M	166.71M	170.35M	154.02M	153.49M	153.15M	152.83M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	154.90M	144.28M	127.04M	107.67M	86.35M	88.64M	145.97M	77.47M
Cost of Goods Sold	41.35M	38.65M	65.11M	54.87M	46.02M	36.19M	61.62M	27.51M
Gross Profit	113.56M	105.64M	61.94M	52.80M	40.33M	52.45M	84.35M	49.96M
Gross Profit Margin	73.3%	73.2%	48.8%	49.0%	46.7%	59.2%	57.8%	64.5%
Total Operating Expenses	116.09M	117.17M	172.55M	227.46M	258.15M	280.61M	295.04M	233.90M
Research & Development	12.43M	16.68M	39.13M	82.70M	130.82M	174.53M	167.38M	140.03M
Selling, General & Administrative	103.67M	100.48M	119.82M	144.75M	127.33M	106.08M	127.66M	93.87M
Operating Income (EBIT)	-2.54M	-11.53M	-110.61M	-174.66M	-217.83M	-228.16M	-210.69M	-183.94M
Operating Margin	-1.6%	-8.0%	-87.1%	-162.2%	-252.3%	-257.4%	-144.3%	-237.4%
Income Before Tax (EBT)	-20.20M	-13.58M	-110.56M	-182.02M	-220.68M	-227.28M	-204.75M	-178.84M
Interest Income	N/A	3.55M	3.36M	1.64M	433K	3.63M	7.26M	5.96M
Interest Expense	N/A	6.03M	3.87M	2.47M	2.41M	1.90M	1.47M	2.67M
Other Income/Expense	-17.66M	-2.05M	56K	-7.37M	-2.85M	885K	5.95M	5.10M
Net Income	-20.20M	-13.58M	-110.56M	-182.02M	-220.68M	-227.28M	-204.75M	-178.84M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-13.0%	-9.4%	-87.0%	-169.1%	-255.6%	-256.4%	-140.3%	-230.8%
EBITDA	-224K	-9.04M	-107.72M	-171.77M	-214.81M	-225.32M	-208.65M	-182.42M
EBITDA Margin	-0.1%	-6.3%	-84.8%	-159.5%	-248.8%	-254.2%	-142.9%	-235.5%
Depreciation & Amortization	2.31M	2.49M	2.90M	2.89M	3.02M	2.85M	2.04M	1.51M
EPS Basic	-0.12	-0.09	-0.80	-1.67	-2.24	-2.50	-2.50	-2.44
EPS Diluted	-0.12	-0.09	-0.80	-1.67	-2.24	-2.50	-2.50	-2.44
Weighted Average Basic Shares	166.71M	152.45M	138.13M	109.00M	98.47M	90.77M	81.78M	73.19M
Weighted Average Diluted Shares	166.71M	152.45M	138.13M	109.00M	98.47M	90.77M	81.78M	73.19M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.